Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.

Yanis Merad,Alexandre Gaymard,Laurent Cotte,Thomas Perpoint,Dulce Alfaiate,Matthieu Godinot,Agathe Becker, Olivier Cannesson, Anne-Sophie Batalla, Fatima Oria-Yassir,Sophie Landré,Florence Morfin,Maude Bouscambert,Florent Valour, Florence Ader,Anne Conrad

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin（2022）

引用 8|浏览18

暂无评分

摘要

Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases.

查看译文

关键词

Modified Vaccinia Virus Ankara,Monkeypox,Mpox,Post-exposure,Vaccination

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要